In a trial employing a modified anti-CD3 monoclonal antibody (mAb) [hOKT3ɣ1 (Ala-Ala)] in T1D patients, Bisikirska et al (2005) [17] originally depicted in responders an increased number and activation of CD8+ T cells upon treatment. This evidence concerns the gene CD8A and type 1 diabetes mellitus.